WALTHAM, Mass.--Genome Therapeutics announced the promotion of Nikolai Kley to vice-president, functional genomics. Kley joined Genome Therapeutics in January 1997 from Bristol-Myers Squibb Pharmaceutical Research Institute. At Genome Therapeutics, Kley and his team have strengthened the firm's functional genomics capabilities, notably in signal pathway analysis, protein interaction networks in yeast and mammalian systems, expression cloning, and drug target validation, according to Robert Hennessey, the company's president. Kley will continue to oversee Genome Therapeutics' functional genomics programs, including exploration of signaling pathways for the p53 tumor suppressor gene to identify new pharmaceutical targets for cancer.
Genome Therapeutics Promotes Kley to VP For Functional Genomics
Nov 14, 1998